Author details

Full Name

Charles W M Roberts

Affiliation

ORCID

Career Start Year

1990

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37225980	Mitotic bookmarking by SWI/SNF subunits.	Nature	2023
35537449	NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.	Mol Cell	2022
35732731	cBAF complex components and MYC cooperate early in CD8<sup>+</sup> T cell fate.	Nature	2022
33753930	A first-generation pediatric cancer dependency map.	Nat Genet	2021
32631955	Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine.	Clin Cancer Res	2020
32303701	The SWI/SNF complex in cancer - biology, biomarkers and therapy.	Nature Reviews Clinical Oncology	2020
32822580	Partitioning of Chemotherapeutics into Nuclear Condensates-Opening the Door to New Approaches for Drug Development.	Molecular Cell	2020
31461650	Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors.	Cell Rep	2019
31558726	Author Correction: BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.	Nat Commun	2019
30595504	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.	Cancer Cell	2019
30755442	MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.	Cancer Res	2019
30753823	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.	Cancer Cell	2019
30860482	Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibition.	Elife	2019
31015438	BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.	Nat Commun	2019
29684361	High Frequency of Ovarian Cyst Development in Vhl<sup>2B/+</sup>;Snf5<sup>+/-</sup> Mice.	Am J Pathol	2018
30224644	Mutational processes shape the landscape of TP53 mutations in human cancer.	Nat Genet	2018
30380416	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer.	Cell Rep	2018
29202477	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.	J Clin Invest	2018
28178232	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.	Nature	2017
28504702	PGBD5 promotes site-specific oncogenic mutations in human tumors.	Nat Genet	2017
28951624	Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors.	Nat Genet	2017
28697319	Renal Medullary Carcinoma: Establishing Standards in Practice.	J Oncol Pract	2017
29272704	AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection.	Molecular Cell	2017
27941798	ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice.	Nat Genet	2017
27941797	SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.	Nat Genet	2017
28262751	The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers.	Nat Commun	2017
26646792	Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.	Oncotarget	2016
26845405	Targeting EZH2 in cancer.	Nature Medicine	2016
26755072	Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.	Neuro Oncol	2016
27329820	Integrated genetic and pharmacologic interrogation of rare cancers.	Nat Commun	2016
26822149	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.	JAMA Oncol	2016
27260156	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.	Cancer Discov	2016
26668377	Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.	Proc Natl Acad Sci U S A	2015
26552009	SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.	Nat Med	2015
26633995	Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia.	Epigenetics Chromatin	2015
26248267	Toward understanding and exploiting tumor heterogeneity.	Nat Med	2015
24562383	ARID1B is a specific vulnerability in ARID1A-mutant cancers.	Nat Med	2014
25512523	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proc Natl Acad Sci U S A	2014
24122795	Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.	Clinical Cancer Research	2014
24434203	CARMA: CARM1 methylation of SWI/SNF in breast cancer.	Cancer Cell	2014
24421395	Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.	Mol Cell Biol	2014
23435428	Activation of Î²-catenin/TCF targets following loss of the tumor suppressor SNF5.	Oncogene	2014
24909177	Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.	Oncogene	2014
25203320	Vulnerabilities of mutant SWI/SNF complexes in cancer.	Cancer Cell	2014
24853101	Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.	Cancer genetics	2014
24520176	Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.	Proc Natl Acad Sci U S A	2014
23723349	Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters.	Proc Natl Acad Sci U S A	2013
24165726	Linking the SWI/SNF complex to prostate cancer.	Nature Genetics	2013
23770567	Mutational heterogeneity in cancer and the search for new cancer-associated genes.	Nature	2013
24204904	Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.	PLoS ONE	2013